Drdgold (DRDGF) Cash & Equivalents (2017 - 2025)

Drdgold has disclosed Cash & Equivalents across 9 years of filings, most recently posting $71.5 million for Q2 2025.

• Cash & Equivalents for Q2 2025 came in at $71.5 million, up 154.49% year-over-year; the trailing twelve-month figure through Jun 2025 was $71.5 million (up 154.49% YoY), and the FY2025 annual result was $71.5 million, up 154.49% from the prior year.
• Cash & Equivalents came in at $71.5 million for Q2 2025 at Drdgold, up from $28.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $163.0 million in Q2 2022 to a low of $28.1 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $132.9 million (2023), against an average of $109.9 million.
• Across the five-year window, Cash & Equivalents plunged 78.85% in 2024 and surged 154.49% in 2025, its largest moves.
• Drdgold's Cash & Equivalents stood at $154.2 million in 2021, then rose by 5.71% to $163.0 million in 2022, then slipped by 18.47% to $132.9 million in 2023, then slumped by 78.85% to $28.1 million in 2024, then soared by 154.49% to $71.5 million in 2025.
• The last three Cash & Equivalents figures came in at $71.5 million (Q2 2025), $28.1 million (Q2 2024), and $132.9 million (Q2 2023), per Business Quant data.